Patents by Inventor Yves Durocher

Yves Durocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010686
    Abstract: Methods and compositions for increasing the production of large amounts of empty capsids of the foot-and-mouth disease virus (FMDV) in a stable manner in mammalian cells by regulating the expression of FMDV 3C protease. The instant methods and compositions are based on the fact that a decreased expression of 3C protease results in a reduced cell toxicity and an increased synthesis of viral capsid proteins, as well as production of recombinant empty capsids. The invention provides recombinant plasmids that direct the expression of P1, 3C, and the use of the plasmids for producing new stable cell lines capable of generating high titers of FMDV empty capsids. The invention provides methods for regulating the expression of the FMDV 3C protease gene at a transcriptional and translational level in order to achieve the required process level of 3C protease for the selection process, as well as the production process.
    Type: Application
    Filed: November 9, 2021
    Publication date: January 11, 2024
    Applicants: Instituto Nacional de Tecnologia Agropecuaria, National Research Council of Canada
    Inventors: Ana Clara Mignaqui, Andres Wigodorovitz, Yves Durocher
  • Publication number: 20230279088
    Abstract: A brain-penetrating composition of amyloid-? binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-? targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 7, 2023
    Inventors: Balu Chakravarthy, Danica Stanimirovic, Yves Durocher
  • Publication number: 20230257424
    Abstract: A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-ß targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.
    Type: Application
    Filed: July 31, 2018
    Publication date: August 17, 2023
    Applicant: National Research Council of Canada
    Inventors: Balu Chakravarthy, Danica Stanimirovic, Yves Durocher
  • Patent number: 11702466
    Abstract: A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-ß targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: July 18, 2023
    Assignee: National Research Council of Canada
    Inventors: Balu Chakravarthy, Danica Stanimirovic, Yves Durocher
  • Publication number: 20230174591
    Abstract: Provided is a recombinant polypeptide comprising a resistin trimerization domain and a polypeptide of interest. Further provided is an expression vector encoding the recombinant polypeptide and a method of expressing the recombinant polypeptide. The polypeptide of interest may be a trimeric viral surface antigen or a portion thereof, such as the ectodomain of the SARS-CoV-2 spike protein. Further provided are compositions, such as immunogenic compositions and vaccines, comprising the recombinant polypeptide.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 8, 2023
    Applicant: National Research Council of Canada
    Inventor: Yves DUROCHER
  • Patent number: 11591408
    Abstract: The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 28, 2023
    Assignee: National Research Council of Canada
    Inventors: Michel Gilbert, Traian Sulea, Maria L. Jaramillo, Yves Durocher, Maurizio Acchione
  • Publication number: 20220363723
    Abstract: The present disclosure relates to the use of an Epstein Barr virus origin of replication (oriP) or a functional fragment thereof in a protein expression construct to increase production of a protein of interest in mammalian cells. Also disclosed are protein expression constructs for increased production of antibodies in mammalian cells, and mammalian cells containing the expression constructs.
    Type: Application
    Filed: October 27, 2020
    Publication date: November 17, 2022
    Applicant: National Research Council of Canada
    Inventors: Yves Durocher, Sylvie Perret, Simon Joubert
  • Publication number: 20220033519
    Abstract: The present document describes an alpha-(1,6)-fucosyltransferase (FUT8) antibody, antigen binding domain thereof, or a fusion protein thereof, operable to inhibit FUT8 activity in a cell, and methods of producing recombinant proteins, in particular antibodies, having reduced fucosylation. The present document also describes methods of inhibiting expression and/or activity of a protein in a cell by expressing an antibody and/or a fusion protein operable to inhibit expression and/or activity of the protein. The antibody, antigen binding domain thereof, or fusion protein thereof may comprise a transmembrane domain of a protein resident in an endoplasmic reticulum (ER), a cis Golgi apparatus, a trans Golgi apparatus, or a combination thereof.
    Type: Application
    Filed: September 20, 2019
    Publication date: February 3, 2022
    Inventors: Yves DUROCHER, Simon JOUBERT
  • Publication number: 20210206842
    Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 8, 2021
    Inventors: Marzia MARTINA, Balu CHAKRAVARTHY, Yves DUROCHER, Mehdi ARBABI-GHAHROUDI, Anne MARCIL, Danica STANIMIROVIC, Traian SULEA, Maria MORENO, Umberto BANDERALI
  • Publication number: 20210087298
    Abstract: The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.
    Type: Application
    Filed: November 8, 2018
    Publication date: March 25, 2021
    Applicant: National Research Council of Canada
    Inventors: Michel GILBERT, Traian SULEA, Maria L. JARAMILLO, Yves DUROCHER, Maurizio ACCHIONE
  • Patent number: 10858629
    Abstract: Disclosed is a new process for the production of recombinant proteins, by transient transfection of suspension-grown human embryonic kidney cells (293 cell line and its genetic variants) with an expression vector, using polyethylenimine (PEI) as a transfection reagent. In a preferred embodiment, the process uses 293E cells expressing the Epstein-Barr virus (EBV) EBNA 1 protein, in combination with an oriP-based episomal expression vector having an improved cytomegalovirus expression cassette comprising the CMV5 promoter. The process combines in a single step the cell growth, transfection and protein expression, is carried out without changing the culture medium, and allows to achieve high expression levels in a short period of time. The process may be carried out in a serum-free, low-protein culture medium, is easily scalable, compatible with continuous production processes, and fully adapted to high-throughput production of milligram quantities of recombinant proteins.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: December 8, 2020
    Assignee: National Research Council of Canada
    Inventors: Yves Durocher, Amine Kamen, Sylvie Perret, Phuong Pham
  • Patent number: 10738115
    Abstract: The present invention relates to antibodies and fragments thereof derived by humanization of an existing antibody, and methods of making them. The humanized antibodies of the present invention show enhanced binding to the brain endothelial antigen, improved transmigration across the blood-brain barrier, and increased thermal stability relative to the parent non-humanized antibody.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: August 11, 2020
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Yves Durocher, Traian Sulea
  • Publication number: 20200010808
    Abstract: Disclosed is a new process for the production of recombinant proteins, by transient transfection of suspension-grown human embryonic kidney cells (293 cell line and its genetic variants) with an expression vector, using polyethylenimine (PEI) as a transfection reagent. In a preferred embodiment, the process uses 293E cells expressing the Epstein-Barr virus (EBV) EBNA 1 protein, in combination with an oriP-based episomal expression vector having an improved cytomegalovirus expression cassette comprising the CMV5 promoter. The process combines in a single step the cell growth, transfection and protein expression, is carried out without changing the culture medium, and allows to achieve high expression levels in a short period of time. The process may be carried out in a serum-free, low-protein culture medium, is easily scalable, compatible with continuous production processes, and fully adapted to high-throughput production of milligram quantities of recombinant proteins.
    Type: Application
    Filed: August 27, 2019
    Publication date: January 9, 2020
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Yves Durocher, Amine Kamen, Sylvie Perret, Phuong Pham
  • Patent number: 10487153
    Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 26, 2019
    Assignee: National Research Council of Canada
    Inventors: Anne E. G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
  • Publication number: 20190352383
    Abstract: A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-ß targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.
    Type: Application
    Filed: January 30, 2018
    Publication date: November 21, 2019
    Applicant: National Research Council of Canada
    Inventors: Balu Chakravarthy, Danica Stanmirovic, Yves Durocher
  • Patent number: 10421950
    Abstract: Disclosed is a new process for the production of recombinant proteins, by transient transfection of suspension-grown human embryonic kidney cells (293 cell line and its genetic variants) with an expression vector, using polyethylenimine (PEI) as a transfection reagent. In a preferred embodiment, the process uses 293E cells expressing the Epstein-Barr virus (EBV) EBNA 1 protein, in combination with an oriP-based episomal expression vector having an improved cytomegalovirus expression cassette comprising the CMV5 promoter. The process combines in a single step the cell growth, transfection and protein expression, is carried out without changing the culture medium, and allows to achieve high expression levels in a short period of time. The process may be carried out in a serum-free, low-protein culture medium, is easily scalable, compatible with continuous production processes, and fully adapted to high-throughput production of milligram quantities of recombinant proteins.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: September 24, 2019
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Yves Durocher, Sylvie Perret, Phuong Lan Pham, Amine A. Kamen
  • Publication number: 20190241653
    Abstract: The present invention relates to antibodies and fragments thereof derived by humanization of an existing antibody, and methods of making them. The humanized antibodies of the present invention show enhanced binding to the brain endothelial antigen, improved transmigration across the blood-brain barrier, and increased thermal stability relative to the parent non-humanized antibody.
    Type: Application
    Filed: July 4, 2017
    Publication date: August 8, 2019
    Applicant: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Yves Durocher, Traian Sulea
  • Publication number: 20180186893
    Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.
    Type: Application
    Filed: June 10, 2016
    Publication date: July 5, 2018
    Applicant: National Research Council of Canada
    Inventors: Anne E.G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
  • Patent number: 9353382
    Abstract: Processes, vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs, the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 31, 2016
    Assignee: National Research Council of Canada
    Inventors: Yves Durocher, Martin Loignon
  • Patent number: 9085627
    Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: July 21, 2015
    Assignee: National Research Council of Canada
    Inventor: Yves Durocher